Objective： To observe the clinical effect of Astragalus Injection （黄芪注射液, Al） and its immuno-regulatory action in treating chronic aplastic anemia （CAA）. Methods： Sixty patients with CAA were randomly assig...Objective： To observe the clinical effect of Astragalus Injection （黄芪注射液, Al） and its immuno-regulatory action in treating chronic aplastic anemia （CAA）. Methods： Sixty patients with CAA were randomly assigned to two groups equally, both were treated with Stanozolol three times a day, 2 mg each time through oral intake, but AI was given additionally to the patients in the treated group once a day via intravenous dripping. All were treated for 15 days as one therapeutic course and the whole medication lasted for more than 4 months totally, with follow-up adopted. The clinical efficacy was estimated and the changes of T-lymphocyte subsets in peripheral blood as well as the serum levels of tumor necrosis factor-α （TNF-α ） and interleukin-2 （IL-2） were observed. Results： The total effective rate in the treated group was 83.3% （25/30）, which was higher than that in the control group 66.7% （20/30）, showing significant difference between them （P〈0.05）. Levels of hemoglobin, WBC, reticular cell and platelet were elevated in both groups after treatment, but the improvement was significantly better in the treated group than that in the control group with respect to the former three indexes （P〈0.05）. The level of CD4^＋ increased and that of CD8^＋ decreased significantly after treatment in the treated group （P〈0.05）, which showed significant difference as compared with those in the control group （P〈0.05）. Levels of serum TNF-α and IL-2 lowered after treatment in both groups, but significance only showed in the treated group （P〈0.05）. The degree of proliferation in bone marrow got raised significantly and the percentage of non-hemopoietic cells reduced significantly in the treated group after treatment, also showing significant difference to those in the control group （P〈0.05）. Conclusion： AI could promote the recovery of hemopoietic function, which might be through improving T-lymphocyte subsets and reducing the release of negative regulatory factors such as TNF-α and IL-2 to alleviate the inhibition on hemopoietic function.展开更多
肿瘤相关性贫血(cancer related anemia,CRA)指肿瘤患者在其疾病的发展以及治疗过程中发生的贫血,是肿瘤患者常见的并发症。CRA对肿瘤患者的生存、疾病进展、生活质量均有一定的影响。出血、慢性炎症、骨髓抑制、缺铁、骨髓浸润等多种...肿瘤相关性贫血(cancer related anemia,CRA)指肿瘤患者在其疾病的发展以及治疗过程中发生的贫血,是肿瘤患者常见的并发症。CRA对肿瘤患者的生存、疾病进展、生活质量均有一定的影响。出血、慢性炎症、骨髓抑制、缺铁、骨髓浸润等多种因素常引起CRA的发生,它们会通过红细胞生成减少或红细胞破坏增加的过程引发贫血。本文主要综述了CRA发展的主要病因和病因途径,以期为肿瘤相关性贫血的研究奠定一定的理论基础。展开更多
基金Supported by the Funds of Langfang Municipal Department of Science and Technology (No 2005050245)
文摘Objective： To observe the clinical effect of Astragalus Injection （黄芪注射液, Al） and its immuno-regulatory action in treating chronic aplastic anemia （CAA）. Methods： Sixty patients with CAA were randomly assigned to two groups equally, both were treated with Stanozolol three times a day, 2 mg each time through oral intake, but AI was given additionally to the patients in the treated group once a day via intravenous dripping. All were treated for 15 days as one therapeutic course and the whole medication lasted for more than 4 months totally, with follow-up adopted. The clinical efficacy was estimated and the changes of T-lymphocyte subsets in peripheral blood as well as the serum levels of tumor necrosis factor-α （TNF-α ） and interleukin-2 （IL-2） were observed. Results： The total effective rate in the treated group was 83.3% （25/30）, which was higher than that in the control group 66.7% （20/30）, showing significant difference between them （P〈0.05）. Levels of hemoglobin, WBC, reticular cell and platelet were elevated in both groups after treatment, but the improvement was significantly better in the treated group than that in the control group with respect to the former three indexes （P〈0.05）. The level of CD4^＋ increased and that of CD8^＋ decreased significantly after treatment in the treated group （P〈0.05）, which showed significant difference as compared with those in the control group （P〈0.05）. Levels of serum TNF-α and IL-2 lowered after treatment in both groups, but significance only showed in the treated group （P〈0.05）. The degree of proliferation in bone marrow got raised significantly and the percentage of non-hemopoietic cells reduced significantly in the treated group after treatment, also showing significant difference to those in the control group （P〈0.05）. Conclusion： AI could promote the recovery of hemopoietic function, which might be through improving T-lymphocyte subsets and reducing the release of negative regulatory factors such as TNF-α and IL-2 to alleviate the inhibition on hemopoietic function.
文摘肿瘤相关性贫血(cancer related anemia,CRA)指肿瘤患者在其疾病的发展以及治疗过程中发生的贫血,是肿瘤患者常见的并发症。CRA对肿瘤患者的生存、疾病进展、生活质量均有一定的影响。出血、慢性炎症、骨髓抑制、缺铁、骨髓浸润等多种因素常引起CRA的发生,它们会通过红细胞生成减少或红细胞破坏增加的过程引发贫血。本文主要综述了CRA发展的主要病因和病因途径,以期为肿瘤相关性贫血的研究奠定一定的理论基础。
